Casebia Therapeutics
Casebia Therapeutics has a corporate name and a web domain that is currently parked with GoDaddy, with no active company content, products, customers, headcount, funding, or management information disclosed in the supplied data.
- Company typePrivate
- Founded2016
- HeadquartersCambridge, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
Casebia Therapeutics firmographics
Firmographics- Name
- Casebia Therapeutics
- Website
- https://casebia.com
- Company type
- Private
- Founded year
- 2016
- Headcount range
- 11–50 employees
- Short description
- Casebia Therapeutics has a corporate name and a web domain that is currently parked with GoDaddy, with no active company content, products, customers, headcount, funding, or management information disclosed in the supplied data.
- Ownership category
- akta.pro rank
Where Casebia Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Markets served
Casebia Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Services
Casebia Therapeutics product offering
Product offeringCore offering
No substantive product or service offering information is available. The company's domain (casebia.com) is parked with GoDaddy and contains no active company content describing what the company fundamentally does or sells.
Differentiator
Problem solved
Functional benefit
Casebia Therapeutics technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Casebia Therapeutics competitors and assessment
Company assessmentDirect peers
- CRISPR Therapeutics: CRISPR Therapeutics is a clinical-stage gene editing company developing CRISPR/Cas9-based medicines. It is the most direct peer because, based on the 'Therapeutics' branding and historical stock-search references, Casebia Therapeutics appears to have been a vehicle operating in the same CRISPR/Cas9 therapeutic modality.
- Editas Medicine: Editas Medicine develops CRISPR/Cas9 and CRISPR/Cas12a gene-editing medicines for serious diseases. It is directly comparable as a clinical-stage gene editing therapeutics peer with overlapping modality and disease focus.
- Intellia Therapeutics: Intellia Therapeutics applies CRISPR/Cas9 for in vivo and ex vivo therapeutic applications. Directly comparable as a gene-editing therapeutics peer with analogous technology platform and pipeline orientation.
- Beam Therapeutics: Beam Therapeutics develops precision genetic medicines using base editing. Closely comparable as a next-generation gene editing therapeutics company with analogous platform-technology business model.
Broad incumbents
- Sangamo Therapeutics: Sangamo Therapeutics is a genomic-medicine company using zinc finger nucleases and other genome-editing approaches. Comparable as a broader incumbent in genomic medicine with overlapping therapeutic ambitions but a non-CRISPR technology base.
Emerging players
- Caribou Biosciences: Caribou Biosciences develops CRISPR-based allogeneic CAR-T cell therapies. Comparable as an emerging player in the CRISPR therapeutics space with an analogous platform approach to engineered cell therapies.
- Prime Medicine: Prime Medicine develops prime editing, a next-generation gene-editing technology, for therapeutic applications. Comparable as an emerging player with adjacent gene-editing therapeutic technology targeting similar disease areas.
Market position
Customer concentration
Casebia Therapeutics social profiles
Digital presenceCasebia Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Casebia Therapeutics leadership team
Management profileNumber of profiles
Casebia Therapeutics funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Casebia Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Casebia Therapeutics
What does Casebia Therapeutics do?
No substantive product or service offering information is available. The company's domain (casebia.com) is parked with GoDaddy and contains no active company content describing what the company fundamentally does or sells.
When was Casebia Therapeutics founded?
Casebia Therapeutics was founded in 2016. It employs 11 to 50 people.
Where is Casebia Therapeutics based?
Casebia Therapeutics is headquartered in Cambridge, United States, in the North America region.
Who are Casebia Therapeutics's main competitors?
Direct peers on record are CRISPR Therapeutics, Editas Medicine, Intellia Therapeutics and Beam Therapeutics. Sangamo Therapeutics is listed as a broad incumbent. Emerging players are Caribou Biosciences and Prime Medicine.
Does Casebia Therapeutics have an API?
No public API is recorded for Casebia Therapeutics.